Epinastine
|  | |
|  | |
| Systematic (IUPAC) name | |
|---|---|
| (RS)-3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine | |
| Clinical data | |
| Trade names | Alesion, Elestat, Purivist, Relestat | 
| AHFS/Drugs.com | monograph | 
| MedlinePlus | a604011 | 
| Pregnancy category | 
 | 
| Routes of administration | Eye drops | 
| Pharmacokinetic data | |
| Protein binding | 64% | 
| Biological half-life | 12 hours | 
| Identifiers | |
| CAS Number | 80012-43-7  | 
| ATC code | R06AX24 (WHO) S01GX10 | 
| PubChem | CID 3241 | 
| IUPHAR/BPS | 7176 | 
| DrugBank | DB00751  | 
| ChemSpider | 3128  | 
| UNII | Q13WX941EF  | 
| KEGG | D07900  | 
| ChEBI | CHEBI:51032  | 
| ChEMBL | CHEMBL1106  | 
| Chemical data | |
| Formula | C16H15N3 | 
| Molar mass | 249.311 g/mol | 
| 
 | |
| 
 | |
| (verify) | |
Epinastine (brand names Alesion, Elestat, Purivist, Relestat) is a second-generation antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis. It is produced by Allergan and marketed by Inspire in the United States.[1] It is highly selective for the H1 receptor and does not cross the blood-brain-barrier.[2]
References
- ↑ Pradhan, S; Abhishek, K; Mah, F (2009). "Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects". Expert opinion on drug metabolism & toxicology 5 (9): 1135–40. doi:10.1517/17425250903117284. PMID 19630694.
- ↑ Walther G, Daniel H, Bechtel WD, Brandt K (April 1990). "New tetracyclic guanidine derivatives with H1-antihistaminic properties. Chemistry of epinastine". Arzneimittel-Forschung 40 (4): 440–6. PMID 1972625.
External links
| 
 | ||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.